Actualités et vidéos - AB SCIENCE - Anglais - Page 2

PRESS RELEASE AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE IN A RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA ( AML ) PATIENT FROM THE VERY LOW DOSE ARM OF ITS AB8939 PHASE I/II CLINICAL TRIAL (AB18001) AB SCIENCE WILL HOST A LIVE WEBCAST ON ITS NEW MICROTUBULE PLATFORM ON T HURSDAY MARCH 1 6 , 2023, FROM 6PM TO 7PM CET Paris, 13 March , 202 3 , 6pm CET AB Science SA (Euronext – FR0010557264 – AB) today announces a case report from the initial stage of its Phase I/II study (AB18001)...

PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN ALZHEIMER'S DISEASE IN THE JOURNAL ALZHEIMER'S RESEARCH & THERAPY Paris, 28 February , 202 3 , 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced publication of results from its positive pivotal phase 3 trial (AB09004) of masitinib in mild-to-moderate Alzheimer’s disease (AD) in the renowned international peer-reviewed journal Alzheimer's Research & Therapy [1]. This article, titled ‘ Masitinib for...

PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE SECOND TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Paris, January 31, 2023 , 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced today that it has received payment of €6.0 million as the second tranche of a €15 million loan from the European Investment Bank (EIB). As previously announced [1], the agreement signed with the EIB provides a financing in two tranches of EUR 6.0 million...

PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS Paris, December 29 2022, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced today that its Phase III clinical trial (AB20009) in progressive forms of multiple sclerosis has been approved by the US Food and Drug Administration (FDA). This decision follows authorizations received from...

PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27 , 202 2 , 7 pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS). As a reminder, masitinib has previously received ODS for ALS from the U.S. Food and Drug...

PRESS RELEASE AB SCIENCE ANNOUNCES THE DRAWDOWN OF THE FIRST TRANCHE OF 6 MILLION EUROS UNDER ITS FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Paris, December 22 , 2022, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced today that it has received payment of €6.0 million as the first tranche of a €15 million loan from the European Investment Bank (EIB). As previously announced [1], the agreement signed with the EIB provides a financing in two tranches of EUR 6.0 million...

PRESS RELEASE AB SCIENCE RECEIVES FIRST AGENCIES AUTHOR I ZATION S TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris, October 10 th 202 2 , 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the first authorizations have been received to initiate its phase 3 confirmatory study (AB21004) evaluating masitinib in patients with mild to moderate Alzheimer's Disease (AD) from the French Medicine Agency (ANSM) together...

PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2022 AND THE KEY EVENTS OF THE PERIOD Clinical development Authorization by Health Canada in February 2022 to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) under the Notice of Compliance with Conditions (NOC/c) policy and formal start of the review in May 2022. Health Canada has a target of 200 calendar days maximum to review the application Filing for conditional...

PRESS RELEASE AB SCIENCE ANNOUNCES PUBLICATION IN THE JOURNAL OF ASTHMA AND ALLERGY OF POSITIVE MASITINIB PHASE 3 CLINICAL TRIAL RESULTS IN PATIENTS WITH ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA Paris, 7 June , 2022, 5.45 pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids (OCS) in the peer-reviewed Journal of Asthma and Allergy [1]. This article, titled...

PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS STARTED THE REVIEW OF NEW DRUG SUBMISSION FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) , FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE LETTER Paris, 2 6 May , 20 22 , 10 pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), meaning that the information...

NOT FOR DISTRIBUTION, PUBLICATION, RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN PRESS RELEASE FINANCING OF 8 .5 MILLION DOLLARS THROUGH THE ISSUANCE OF CONVERTIBLE BONDS WITH ATTACHED WARRANTS (WITH A CONVERSION PRICE OF EUR 14 . 0) Paris, France – February 2 8 , 2022 , 8am AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) announces today that it reached an agreement with a historical investor on a financing of...

PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY FEBRUARY 2 8 , 2022 TO PROVIDE DETAILS ON THE MASITINIB FILING IN THE TREATMENT OF ALS IN CANADA AND TO PROVIDE UPDATE ON ITS CLINICAL PROGRAM IN ALL INDICATIONS Paris, February 24, 2022, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment of amyotrophic lateral sclerosis (ALS) in Canada under the NOC/c procedure and to provide...

PRESS RELEASE AB SCIENCE HAS BEEN AUTHORIZED BY THE SWEDISH MEDICAL PRODUCTS AGENCY TO INITIATE CONFIRMATORY PHASE III TRIAL OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS SWEDEN IS THE SECOND EUROPEAN COUNTRY TO AUTHORIZE THE STUDY AFTER THE APPROVAL RECEIVED BY THE FRENCH MEDICINE AGENCY Paris, 02 February , 2022, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the Swedish Medical Products Agency, to initiate a Phase III study...

PRESS RELEASE AB SCIENCE HAS BEEN GRANTED AUTHORIZATION TO INITIATE CONFIRMATORY PHASE III TRIAL OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS BY THE FRENCH HEALTH AUTHORITY (ANSM) Paris, 03 January , 2021, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary...

PRESS RELEASE AB SCIENCE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 TRIAL OF MASITINIB’S ANTIVIRAL ACTIVITY AGAINST THE SARS-CoV-2 ( COVID-19 ) VIRUS Paris, 29 November , 2021, 8.45 pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19. The study plans to enroll 78 patients, either non-hospitalized patients with mild...

PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW GENERATION SYNTHETIC MICROTUBULE DESTABILIZER WITH THE ABILITY TO OVERCOME MULTIDRUG RESISTANCE AND HAS BROAD APPLICABILITY AS A POTENT ANTICANCER DRUG Paris, November 22 , 2021, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that its Phase I/II study (AB18001) evaluating AB8939 in...

PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO RESUME PATIENT ENROLMENT IN THE PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) STUDY AB19001 HAS NOW BEEN AUTHORIZED IN 15 COUNTRIES IN EUROPE , USA, AND OTHER REGIONS AND IS ACTIVELY ENROLLING PATIENTS Paris, 1 8 November 2021, 8 .30 pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has received authorization from the United States Food and Drug Administration...

PRESS RELEASE AB SCIENCE GRANTED AUTHORIZATION FROM THE FRENCH HEALTH AUTHORITY (ANSM) TO INITIATE A STUDY OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) SECOND AUTHORIZATION FOR PHASE I/II TRIAL AB18001 PERMITS PATIENT RECRUITMENT FROM STUDY SITES IN FRANCE AND CANADA Paris, 18 October , 2021, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase I/II study (AB18001) evaluating AB8939...

PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2021 AND THE KEY EVENTS OF THE PERIOD Financial information Operating loss of €6.0 million, a 12.4% reduction in expenses as compared to 2020 Significant financial visibility, with a cash position of €17.7 million as of 30 June 2021, plus €3.3 million of 2020 tax credit to be reimbursed by the Public Finance Department and with off-balance sheet commitments received amounting to €90 million Clinical...

PRESS RELEASE AB SCIENCE RECEIVES REGULATORY AUTHORIZATION TO COMMENCE A SECOND PHASE 2 COVID STUDY STUDY DESIGN FOCUSES DIRECTLY ON MASITINIB’S ANTIVIRAL ACTIVITY AGAINST THE COVID-19 VIRUS ( SARS-CoV-2 ) FOR THE TREATMENT OF PATIENTS AT AN EARLY STAGE OF THE DISEASE WITH TWO PHASE 2 STUDIES , MASITINIB IS A LEADING CANDIDATE IN THE DEVELOPMENT OF ORAL PROTEASE INHIBITOR S FOR TREATMENT OF NON-HOSPITALIZED AND HOSPITALIZED COVID-19 PATIENTS Paris, 28 September , 2021, 7 pm CET AB Science SA...